Buy Osicent 80MG (Osimertinib) - Mediaid pharmacy

Osicent 80MG (Osimertinib)

Product Name : Osicent
Generic Name : Osimertinib
Formulation : Tablet
Available Pack Size : 30’s
Available Strengths : 80 mg
Registrations : Export Only

Message Us on WhatsApp

Product Information

Osicent (Osimertinib) 80mg is a third-generation, irreversible EGFR tyrosine kinase inhibitor (EGFR-TKI) used to treat EGFR mutation-positive Non-Small Cell Lung Cancer (NSCLC), including tumours with exon 19 deletions, exon 21 L858R mutations, and the T790M resistance mutation. It works by irreversibly binding to mutant EGFR proteins, blocking the signalling pathway that drives tumour cell growth and survival, while sparing wild-type EGFR to a much greater extent than earlier-generation TKIs, and shows strong penetration into the central nervous system for patients with brain metastases. Manufactured by Incepta Pharmaceuticals Ltd., Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.

Basic Product Information of Osicent (Osimertinib) 80mg

Brand Name	Osicent (Osimertinib)
Generic Name	Osimertinib (as Osimertinib Mesylate) INN, 80mg
Drug Class	Third-Generation, Irreversible EGFR Tyrosine Kinase Inhibitor (EGFR-TKI)
Available Strength	80mg
Formulation	Film-Coated Tablet
Pack Size	30 Tablets per Bottle
Primary Indication	EGFR Mutation-Positive Non-Small Cell Lung Cancer (Exon 19 Deletion, Exon 21 L858R, and T790M Resistance Mutation)
Regulatory Approvals	USFDA Approved (First-Line and T790M-Positive NSCLC). EMA Approved.
Originator Brand	Tagrisso by AstraZeneca
Manufacturer	Incepta Pharmaceuticals Ltd., Dhaka, Bangladesh
Global Supplier	Mediaid Pharmacy, Worldwide Shipping Available
Registration Status	Export Only – Manufactured for International Markets
Storage Conditions	Store below 30 degrees Celsius. Protect from moisture and light. Keep out of the reach of children.

How Osicent (Osimertinib) Works

Osicent contains Osimertinib, a third-generation, irreversible inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. In certain non-small cell lung cancers, mutations in the EGFR gene, most commonly exon 19 deletions and the exon 21 L858R substitution, cause the receptor to signal continuously, driving uncontrolled tumour cell growth and survival.

Osimertinib binds irreversibly to these mutant EGFR forms, including the T790M resistance mutation that commonly develops after treatment with earlier-generation EGFR-TKIs, at substantially lower concentrations than are needed to affect normal, wild-type EGFR. By selectively shutting down mutant EGFR signalling, Osicent halts tumour proliferation, and its favourable penetration of the central nervous system makes it particularly useful for patients with brain metastases, a frequent complication of EGFR-mutated NSCLC.

Because of this mutant-selective mechanism, Osicent is classified as a targeted therapy rather than conventional chemotherapy, allowing it to act on cancer cells more precisely while producing a different, generally more manageable side-effect profile. It is taken as a convenient once-daily oral tablet.

Indications for Osicent (Osimertinib)

Osicent (Osimertinib) is indicated for the following conditions:

First-Line Metastatic NSCLC

For the first-line treatment of adult patients with metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an approved test.

T790M-Positive NSCLC

For adult patients with metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed on or after prior EGFR-TKI therapy.

Benefits of Osicent (Osimertinib) 80mg

Strong CNS Penetration

Osicent shows strong penetration into the central nervous system, making it particularly effective against brain metastases, a common and difficult-to-treat complication of EGFR-mutated NSCLC.

Convenient Once-Daily Dosing

Osicent is taken as a single oral tablet once daily, offering a simple, convenient regimen compared to intravenous chemotherapy schedules.

Effective Against Resistance Mutations

Unlike first and second-generation EGFR-TKIs, Osicent retains activity against the T790M resistance mutation, extending treatment options for patients who have progressed on earlier therapy.

Affordable Alternative to Tagrisso

Osicent contains the same active ingredient as Tagrisso by AstraZeneca, at a significantly lower cost, making long-term targeted lung cancer therapy financially accessible for patients worldwide.

Improved Survival Outcomes

Clinical trials of Osimertinib demonstrated significant improvements in progression-free and overall survival compared to earlier-generation EGFR-TKIs.

Backed by an Established Manufacturer

Produced by Incepta Pharmaceuticals Ltd., one of Bangladesh’s largest and fastest-growing pharmaceutical companies, with an extensive oncology manufacturing portfolio and exports to over 100 countries.

How to Take Osicent (Osimertinib)

Route: Oral, taken by mouth. Tablets should be swallowed whole and not chewed, crushed, dissolved, or divided.

Standard dose: 80mg (one tablet) once daily, taken at approximately the same time each day, until disease progression or unacceptable toxicity, exactly as directed by the prescribing oncologist.

With food: Can be taken with or without food, at any time of the day.

Missed dose: If a dose is missed by more than 12 hours, skip that dose and take the next dose at its normal scheduled time; do not double up doses.

Difficulty swallowing: For patients who cannot swallow tablets whole, disperse the tablet in 60mL (2 ounces) of non-carbonated water only, stirring until dispersed into small pieces (the tablet will not fully dissolve), and swallow immediately. Do not crush, heat, or ultrasonicate the tablet during preparation.

Dose reduction for toxicity: If a dose reduction is required to manage adverse reactions such as QTc prolongation, rash, diarrhoea, or other toxicity, the dose may be reduced to a lower strength once daily, as directed by the prescribing physician.

Renal impairment: No dose adjustment is required in patients with mild to moderate renal impairment. Osicent has not been studied in severe renal impairment.

Hepatic impairment: No dose adjustment is required in patients with mild or moderate hepatic impairment. Osicent is not recommended for patients with severe hepatic impairment due to a lack of safety data.

Strong CYP3A4 inducers: Concomitant use should be avoided where possible, as these (including rifampin, phenytoin, carbamazepine, and St. John’s Wort) may decrease Osimertinib plasma concentrations. If unavoidable, dose increases may be considered under close physician supervision.

Paediatric use: The safety and efficacy of Osicent in children and adolescents have not been established. No data are currently available.

Prescription Medication. Treatment with Osicent should not be initiated without confirmed EGFR mutation status from an approved test. Baseline and periodic assessment of left ventricular ejection fraction (LVEF) and ECG (QTc interval) is required, and treatment must be withheld or permanently discontinued if interstitial lung disease, pneumonitis, or severe cardiac or eye toxicity is suspected or confirmed. Always follow your prescribing oncologist’s instructions.

Monitoring and Dosage Adjustments

Regular monitoring is essential during Osicent treatment. Your healthcare provider will monitor for interstitial lung disease (ILD) and pneumonitis, assessing for new or worsening respiratory symptoms such as shortness of breath, cough, or fever. Monitoring also includes left ventricular ejection fraction (LVEF) at baseline and every 3 months, ECG monitoring for QTc prolongation in patients with risk factors, eye symptoms suggestive of keratitis, and periodic blood counts and liver function tests. The most commonly observed side effects requiring dose reduction or interruption include QTc prolongation and neutropenia. Report any breathlessness, chest pain, palpitations, visual changes, or eye irritation to your doctor immediately.

Drug Interactions and Important Information

Avoid concomitant use of Osicent with strong CYP3A4 inducers such as rifampicin, phenytoin, carbamazepine, and St. John’s Wort, as these significantly reduce Osimertinib plasma exposure and may reduce efficacy. Caution is advised with drugs that are sensitive substrates of BCRP or P-glycoprotein (P-gp), as Osimertinib may alter their exposure. Strong CYP3A4 inhibitors are not expected to meaningfully alter Osimertinib exposure based on population data.

Use caution when combining Osicent with other medicines known to prolong the QTc interval. Women of childbearing potential must use effective contraception during treatment and for at least 2 months (women) or 4 months (men) after the final dose. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Osicent.

Side Effects and Precautions

Common Side Effects

Diarrhoea (reported in approximately 42% of patients)

Rash (approximately 41%) and dry skin (approximately 31%)

Nail toxicity, or paronychia (approximately 25%)

Stomatitis (mouth inflammation)

Fatigue

Decreased appetite

Nausea and constipation

Serious Warnings and Precautions

Interstitial lung disease (ILD) and pneumonitis, which can be fatal. Withhold and permanently discontinue if confirmed.

QTc interval prolongation, which may lead to life-threatening arrhythmia. Requires ECG and electrolyte monitoring.

Cardiomyopathy with reduced left ventricular ejection fraction. Requires baseline and 3-monthly LVEF assessment.

Keratitis and other eye toxicities. Report eye pain, redness, or visual disturbance promptly.

Neutropenia, one of the most common reasons for dose reduction or interruption.

Embryo-foetal toxicity. Not recommended during pregnancy or breastfeeding.

Who Should Use Osicent (Osimertinib)?

Osicent is suitable for adult patients diagnosed with locally advanced or metastatic Non-Small Cell Lung Cancer whose tumours carry EGFR exon 19 deletions, exon 21 L858R mutations, or the T790M resistance mutation, confirmed by an approved EGFR mutation test on tissue or blood (liquid biopsy). It is prescribed by medical oncologists and thoracic oncology specialists experienced in biomarker-guided cancer therapy. A thorough medical assessment including EGFR mutation testing, cardiac evaluation (ECG and LVEF), and liver function is required before initiating treatment.

Manufacturer: Incepta Pharmaceuticals Ltd.

Incepta Pharmaceuticals Ltd. is the second-largest pharmaceutical company in Bangladesh, established in 1999 and now among the fastest-growing manufacturers in the country. Incepta operates large-scale manufacturing facilities at Zirabo (Savar) and Dhamrai, producing a wide range of dosage forms, and exports its products to over 100 countries worldwide. The company maintains an extensive oncology portfolio and has continued to expand into complex biologics and specialty generics. Osicent is one of Incepta’s oncology products, offering a bioequivalent alternative to Tagrisso by AstraZeneca at a fraction of the cost.

Global Supplier: Mediaid Pharmacy with Worldwide Shipping

Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Osicent (Osimertinib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.

Why Choose Osicent (Osimertinib) from Mediaid Pharmacy?

Osicent represents a major advancement in the targeted treatment of EGFR-mutated lung cancer. As the generic equivalent of Tagrisso by AstraZeneca, it delivers the same active ingredient, Osimertinib, with the same proven mutant-selective EGFR-inhibition mechanism at a dramatically more affordable price. Manufactured by Incepta Pharmaceuticals Ltd., one of Bangladesh’s largest and most established pharmaceutical companies, and distributed globally by Mediaid Pharmacy, Osicent gives patients worldwide access to high-quality targeted lung cancer therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Osimertinib option with worldwide delivery, Osicent from Mediaid Pharmacy is the trusted choice.

Frequently Asked Questions About Osicent (Osimertinib)

What is Osicent (Osimertinib) used for?

Osicent (Osimertinib) is a third-generation EGFR-TKI used as first-line treatment for adult patients with metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 L858R mutations, and for patients with T790M mutation-positive NSCLC whose disease has progressed after prior EGFR-TKI therapy. It works by blocking the abnormal EGFR signalling that drives tumour growth, with strong activity against brain metastases.

How should I take Osicent (Osimertinib)?

Osicent is taken orally once daily, with or without food, at approximately the same time each day. The standard dose is 80mg (one tablet) once daily. Patients who cannot swallow tablets whole can disperse the tablet in non-carbonated water as directed. Always follow your physician’s exact instructions.

What strength is Osicent (Osimertinib) available in?

This Osicent pack is available in an 80mg film-coated tablet, supplied in a bottle of 30 tablets. The 80mg strength is the standard recommended dose for most adult patients with EGFR-mutated NSCLC.

Is Osicent the same as Tagrisso (Osimertinib by AstraZeneca)?

Yes. Osicent is the generic equivalent of Tagrisso. Both contain the same active ingredient, Osimertinib, in the same dosage form and strength. Osicent is manufactured by Incepta Pharmaceuticals Ltd. in Bangladesh and delivers the same clinical mechanism as Tagrisso at a significantly lower cost, making it a more accessible option for patients worldwide.

What are the side effects of Osicent (Osimertinib)?

Common side effects include diarrhoea, rash, dry skin, nail toxicity, mouth inflammation, fatigue, and decreased appetite. Serious but less common risks include interstitial lung disease, QTc prolongation, reduced heart function, and eye toxicity. Always consult your physician for a complete assessment of your individual risks and benefits before starting treatment.

Can Osicent be used with other medications?

Osicent should not be combined with strong CYP3A4 inducers such as rifampicin, phenytoin, or carbamazepine, as these reduce its effectiveness. Caution is needed with P-glycoprotein and BCRP substrate medications, and with other medicines that prolong the QTc interval. Always inform your physician of all medications, supplements, and herbal products you are taking before starting Osicent.

Is Osicent (Osimertinib) safe during pregnancy or breastfeeding?

No. Osicent is not recommended during pregnancy or breastfeeding, as it can cause foetal harm. Women of childbearing potential must use effective contraception during treatment and for at least 2 months after the final dose, and men should use contraception for at least 4 months after their final dose. Please consult your physician before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding.

Can I order Osicent (Osimertinib) online with worldwide shipping?

Yes. Mediaid Pharmacy supplies Osicent (Osimertinib) 80mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.

Order Osicent (Osimertinib) 80mg with Worldwide Shipping

Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com

Message on WhatsApp